Loading…

Loading grant details…

Active HORIZON European Commission

Innovative Applications of Extracorporeal Photopheresis in Solid Organ Transplantation


Funder European Commission
Recipient Organization Klinikum Der Universitaet Regensburg
Country Germany
Start Date Sep 01, 2023
End Date Aug 31, 2027
Duration 1,460 days
Number of Grantees 21
Roles Participant; Associated Partner; Coordinator
Data Source European Commission
Grant ID 101119855
Grant Description

Organ transplantation remains the only definitive treatment for end-stage heart, lung, liver or kidney disease. Early transplant outcomes are now generally excellent, dramatically reducing patients’ mortality and morbidity.

Nevertheless, transplantation still faces significant obstacles, especially long-term immunosuppression-related toxicity and chronic decline of transplant function, which are the leading causes of transplant failure.

To break these barriers, which represent a very significant societal and economic burden in the EU, there is a need for innovative therapies to lessen our reliance on conventional immunosuppression and better control non-resolving inflammation.

Extracorporeal photopheresis (ECP) is now being investigated as a personalized, adjunct immunosuppressive therapy in some organ transplant settings.

However, ECP is regarded as a controversial therapy, primarily because current understanding of its pharmacological actions is incomplete, but also because there remain questions about optimal manufacturing processes, quality-control and personalized clinical indications.

The exTra project asks whether a better mechanistic understanding of ECP can guide us more efficiently towards novel applications.

Specifically, exTra brings together European experts in clinical transplantation, immunology, pharmaceutical development, computational biology and medical device manufacture to address key questions through a coordinated, interdisciplinary effort. exTra proposes 10 independent doctoral research projects with the ambition of providing its trainees with a comprehensive understanding of basic and translational immunology, especially relating development and licensing of new immunotherapies.

Through its research and training activities, the exTra project will contribute to scientific advancement and innovation in Europe, ultimately leading to societal and economic benefits stemming from clinical innovations in transplant immunotherapy and beyond.

All Grantees

Medizinische Universitaet Wien; Universitaet Regensburg; Quell Therapeutics Limited; Friedrich-Alexander-Universitaet Erlangen-Nuernberg; Immunotech Sas; Instituto de Salud Carlos Iii; Klinikum Der Universitaet Regensburg; Albert-Ludwigs-Universitaet Freiburg; Aniling; Stichting Sanquin Bloedvoorziening; Amedes Medizinische Dienstleistungen Gmbh; Innovation Acta Srl; Institut de Investigacio En Ciencies de la Salut Germans Trias I Pujol; Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer; Universitat de Barcelona; Universitat Autonoma de Barcelona; Therakos Uk Ltd; Universitatsklinikum Erlangen; Universitaetsklinikum Freiburg; Universiteit Van Amsterdam; King's College London

Advertisement
Apply for grants with GrantFunds
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant